Jonathan E Schoenhals
Overview
Explore the profile of Jonathan E Schoenhals including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
667
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tos S, Hajikarimloo B, Mantziaris G, Shaaban A, Pham D, Dayawansa S, et al.
J Clin Neurosci
. 2024 Oct;
129:110879.
PMID: 39426317
Background: Hemangioblastomas (HBs) are rare, benign central nervous system (CNS) neoplasms that rarely occur in the supratentorial. Resection with the goal of gross total resection (GTR) is often considered the...
2.
Upadhyay R, Palmer J, Klamer B, Perlow H, Schoenhals J, Ghose J, et al.
Adv Radiat Oncol
. 2024 May;
9(7):101509.
PMID: 38799108
Background: Current standard of care treatment for patients with ≥15 brain metastases (BM) is whole brain radiation therapy (WBRT), despite poor neurocognitive outcomes. We analyzed our institutional experience of treating...
3.
Schoenhals J, Mohamad O, Christie A, Zhang Y, Li D, Singla N, et al.
Adv Radiat Oncol
. 2021 Oct;
6(5):100692.
PMID: 34646963
Purpose: Oligoprogression, defined as limited sites of progression on systemic therapy, in patients with metastatic renal cell carcinoma (mRCC) is not uncommon, possibly because of inter- and intratumoral heterogeneity. We...
4.
Barsoumian H, Ramapriyan R, Younes A, Caetano M, Menon H, Comeaux N, et al.
J Immunother Cancer
. 2020 Oct;
8(2).
PMID: 33106386
Background: Despite some successes with checkpoint inhibitors for treating cancer, most patients remain refractory to treatment, possibly due to the inhibitory nature of the tumor stroma that impedes the function...
5.
Cortez M, Masrorpour F, Ivan C, Zhang J, Younes A, Lu Y, et al.
Nat Commun
. 2020 Oct;
11(1):5144.
PMID: 33033261
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
6.
Cortez M, Masrorpour F, Ivan C, Zhang J, Younes A, Lu Y, et al.
Nat Commun
. 2020 Sep;
11(1):4840.
PMID: 32973129
Immunotherapies revolutionized cancer treatment by harnessing the immune system to target cancer cells. However, most patients are resistant to immunotherapies and the mechanisms underlying this resistant is still poorly understood....
7.
Caetano M, Younes A, Barsoumian H, Quigley M, Menon H, Gao C, et al.
Clin Cancer Res
. 2019 Sep;
25(24):7576-7584.
PMID: 31540976
Purpose: Radiotherapy (RT) traditionally has been used for local tumor control in the treatment of cancer. The recent discovery that radiotherapy can have anticancer effects on the immune system has...
8.
Li A, Barsoumian H, Schoenhals J, Caetano M, Wang X, Menon H, et al.
Int J Radiat Oncol Biol Phys
. 2019 Mar;
104(4):903-912.
PMID: 30905636
Purpose: The limitation of hypofractionated radiation efficacy is due partly to the immunosuppressive tumor microenvironment. Indoleamine 2,3-dioxygenase 1 (IDO1) is an important regulator of tumor immune suppression. We evaluated the...
9.
Menon H, Ramapriyan R, Cushman T, Verma V, Kim H, Schoenhals J, et al.
Front Immunol
. 2019 Mar;
10:193.
PMID: 30828330
In recent decades, there has been substantial growth in our understanding of the immune system and its role in tumor growth and overall survival. A central finding has been the...
10.
Schoenhals J, Cushman T, Barsoumian H, Li A, Cadena A, Niknam S, et al.
Front Immunol
. 2018 Oct;
9:2170.
PMID: 30294332
Despite the potential to cure metastatic disease, immunotherapy on its own often fails outright or early on due to tumor immune evasion. To address this obstacle, we investigated combinations of...